Successful IGHy self-administration depends on proper patient training and continuing interaction between the health care team and the patient to optimize the patient experience” Miars et al (2016).
An approved subcutaneous infusion of immunoglobulin G using recombinant human hyaluronidase (IGHy) allows adult patients with primary immunodeficiency disease to self-administer every 3 to 4 weeks using 1 to 2 subcutaneous infusion site(s). This article reviews the practical considerations for nurses to simplify patient education and training. Key considerations include pump choice and parameters, ancillary supplies, and technique. Patient education includes infusion log upkeep and management of potential reactions. Educational initiatives should be designed to meet specific patient needs. Successful IGHy self-administration depends on proper patient training and continuing interaction between the health care team and the patient to optimize the patient experience.
ReTweet if useful… Practical considerations for self-administration of subcutaneous immunoglobulin G http://ctt.ec/7fb9V+ @ivteam #ivteam
Miars, L.K., Tran, M. and Duff, K. (2016) Practical Considerations for Self-Administration of Subcutaneous Immunoglobulin G Utilizing Recombinant Human Hyaluronidase, an Advanced Method of Subcutaneous Administration: A Nurse’s Perspective. Journal of Infusion Nursing. 39(6), p.359-368.
Thank you to our partners for supporting IVTEAM